Senolytic vaccination improves normal and pathological age-related phenotypes and increases lifespan in progeroid mice
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Elimination of senescent cells (senolysis) was recently reported to improve normal and pathological changes associated with aging in mice 1,2 . However, most senolytic agents inhibit antiapoptotic pathways 3 , raising the possibility of off-target effects in normal tissues. Identification of alternative senolytic approaches is therefore warranted. Here we identify glycoprotein nonmetastatic melanoma protein B (GPNMB) as a molecular target for senolytic therapy. Analysis of transcriptome data from senescent vascular endothelial cells revealed that GPNMB was a molecule with a transmembrane domain that was enriched in senescent cells (seno-antigen). GPNMB expression was upregulated in vascular endothelial cells and/or leukocytes of patients and mice with atherosclerosis. Genetic ablation of Gpnmb-positive cells attenuated senescence in adipose tissue and improved systemic metabolic abnormalities in mice fed a high-fat diet, and reduced atherosclerotic burden in apolipoprotein E knockout mice on a high-fat diet. We then immunized mice against Gpnmb and found a reduction in Gpnmb-positive cells. Senolytic vaccination also improved normal and pathological phenotypes associated with aging, and extended the male lifespan of progeroid mice. Our results suggest that vaccination targeting seno-antigens could be a potential strategy for new senolytic therapies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Certain cell surface proteins tend to be more highly expressed by senescent cells than most other cell types, which prompted development of engineered chimeric antigen receptor (CAR) T cells, vaccines and antibody–drug conjugates targeting these cell surface markers.”
From Cellular senescence and senolytics: the path to the clinic (2022) · cites this paper as [98]
In the citing paper
“Each of these approaches eliminates senescent cells, although in some cases, activated macrophages and other non-senescent cell types are also affected96–99.”
From Cellular senescence and senolytics: the path to the clinic (2022) · cites this paper as [98]
In the citing paper
“In particular, antibodies directed against the glycoprotein NMB (GPNMB) 202 and CAR T cells directed against the receptor uPAR 203 attenuate senescence-associated disease models in mice.”
From Hallmarks of aging: An expanding universe (2023) · cites this paper as [202]
In the citing paper
“Genetic elimination of GPNMB-positive cells reduces the senescent cell burden and alleviates metabolic irregularities in obese mice. Vaccination against GPNMB also improves a number of conditions associated with aging [13].”
From The heterogeneity of cellular senescence: insights at the single-cell level (2023) · cites this paper as [13]
In the citing paper
“Additionally, a separate study investigated the transcriptomes of vascular endothelial cells and identified GPNMB, a cell-surface protein, as a marker for senescent cells, which was evidenced by its enrichment in senescent vascular endothelial cells compared with non-senescent cells in both human patients and mice with atherosclerosis.”
From The heterogeneity of cellular senescence: insights at the single-cell level (2023) · cites this paper as [13]
Citations
Cites
Krogh, A., Larsson, B., von Heijne, G., & Sonnhammer, E. L. L. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.4315 · Cited by 12,654
NCBI GEO: archive for functional genomics data sets—update
Barrett, T., Wilhite, S. E., Ledoux, P., Evangelista, C., Kim, I. F., Tomashevsky, M., Marshall, K. A., Phillippy, K. H., Sherman, P. M., Holko, M., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1193 · Cited by 10,418
KEGG for linking genomes to life and the environment
Kanehisa, M., Araki, M., Goto, S., Hattori, M., Hirakawa, M., Itoh, M., Katayama, T., Kawashima, S., Okuda, S., Tokimatsu, T., et al. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm882 · Cited by 6,782
Self-citationNaturally occurring p16Ink4a-positive cells shorten healthy lifespan
Baker, D. J., Childs, B. G., Durik, M., Wijers, M. E., Sieben, C. J., Zhong, J., A. Saltness, R., Jeganathan, K. B., Verzosa, G. C., Pezeshki, A., et al. (2016) · Nature · doi:10.1038/nature16932 · Cited by 2,876
Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors
Campisi, J. (2005) · Cell · doi:10.1016/j.cell.2005.02.003 · Cited by 2,379
Senolytics improve physical function and increase lifespan in old age
Xu, M., Pirtskhalava, T., Farr, J. N., Weigand, B. M., Palmer, A. K., Weivoda, M. M., Inman, C. L., Ogrodnik, M. B., Hachfeld, C. M., Fraser, D. G., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0092-9 · Cited by 2,287
Senescent cells: an emerging target for diseases of ageing
Childs, B. G., Gluscevic, M., Baker, D. J., Laberge, R.-M., Marquess, D., Dananberg, J., & van Deursen, J. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.116 · Cited by 1,284
Senolytic drugs: from discovery to translation
Kirkland, J. L., & Tchkonia, T. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13141 · Cited by 1,227
Endothelial Cell Senescence in Human Atherosclerosis: Role of Telomere in Endothelial Dysfunction
Minamino, T., Miyauchi, H., Yoshida, T., Ishida, Y., Yoshida, H., & Komuro, I. (2002) · Circulation · doi:10.1161/01.cir.0000013836.85741.17 · Cited by 1,061
Self-citationA crucial role for adipose tissue p53 in the regulation of insulin resistance
Minamino, T., Orimo, M., Shimizu, I., Kunieda, T., Yokoyama, M., Ito, T., Nojima, A., Nabetani, A., Oike, Y., Matsubara, H., et al. (2009) · Nature Medicine · doi:10.1038/nm.2014 · Cited by 891
Self-citation
Cited by
Hallmarks of aging: An expanding universe
López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2023) · Cell · doi:10.1016/j.cell.2022.11.001 · Cited by 6,549
Cellular senescence and senolytics: the path to the clinic
Chaib, S., Tchkonia, T., & Kirkland, J. L. (2022) · Nature Medicine · doi:10.1038/s41591-022-01923-y · Cited by 1,134
Epigenetic regulation of aging: implications for interventions of aging and diseases
Wang, K., Liu, H., Hu, Q., Wang, L., Liu, J., Zheng, Z., Zhang, W., Ren, J., Zhu, F., & Liu, G.-H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01211-8 · Cited by 663
“More recently, the concept of aging vaccines was proposed, and glycoprotein nonmetastatic melanoma protein (GPNMB) vaccination has been shown to decrease tissue senescence and alleviate aging-related phenotypes.(30) However, how epigenetic mechanisms are involved in these aging-intervention approaches has just begun t…”
BackgroundCellular senescence: a key therapeutic target in aging and diseases
Zhang, L., Pitcher, L. E., Yousefzadeh, M. J., Niedernhofer, L. J., Robbins, P. D., & Zhu, Y. (2022) · Journal of Clinical Investigation · doi:10.1172/jci158450 · Cited by 631
“1172/JCI158450 ciated with aging, and extended lifespan (126).”
BackgroundCAR T therapy beyond cancer: the evolution of a living drug
Baker, D. J., Arany, Z., Baur, J. A., Epstein, J. A., & June, C. H. (2023) · Nature · doi:10.1038/s41586-023-06243-w · Cited by 504
“Another potential target, glycoprotein non-metastatic melanoma protein B (GPNMB), has been described as a senoantigen in endothelial cells 66 .”
Metadata
- Authors
- Suda, M., Shimizu, I., Katsuumi, G., Yoshida, Y., Hayashi, Y., Ikegami, R., Matsumoto, N., Yoshida, Y., Mikawa, R., Katayama, A., Wada, J., Seki, M., Suzuki, Y., Iwama, A., Nakagami, H., Nagasawa, A., Morishita, R., Sugimoto, M., Okuda, S., Tsuchida, M., Ozaki, K., Nakanishi-Matsui, M., & Minamino, T.
- Affiliations
- Juntendo University (JP)
- Niigata University (JP)
- Iwate Medical University (JP)
- Research Institute, National Center for Geriatrics and Gerontology (JP)
- Okayama University (JP)
- The University of Tokyo (JP)
- Institute of Medical Science, The University of Tokyo (JP)
- The University of Osaka (JP)
- Japan Agency for Medical Research and Development (JP)
- Corresponding author
- Minamino, Tohru
- ORCID
- Venue
- Nature Aging
- Published
- 2021-12-10
- Volume
- 1
- Issue
- 12
- Pages
- 1117-1126
- ISSN
- 2662-8465 (ISSN-L)
- OpenAlex
- W4200273754
- Cited by
- 290
- References
- 27
- Citations by year
- 2026: 61 · 2025: 69 · 2024: 84 · 2023: 48 · 2022: 27 · 2021: 1
- FWCI
- 25.14
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature Aging (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Ministry of Education, Culture, Sports, Science and Technology (18K08063, 20H00533)
- Japan Agency for Medical Research and Development (JP20ek0210114, JP20gm1110012, 21zf0127003s0201)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
- Keywords
- senolysis, senescent cells, GPNMB, aging, lifespan extension, progeroid mice, atherosclerosis, vascular endothelial cells, adipose tissue senescence, high-fat diet, ApoE-deficient mice, metabolic abnormalities, anti-senescence therapy
- MeSH terms
- Senotherapeutics, Animals, Longevity, Male, Phenotype, Cellular Senescence, Mice, Knockout, Endothelial Cells, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Senolytic vaccination improves normal and pathological age-related phenotypes and increases lifespan in progeroid mice. https://app.cochat.ai/papers/10.1038/s43587-021-00151-2
- The paper
- Suda, M., Shimizu, I., Katsuumi, G., Yoshida, Y., Hayashi, Y., Ikegami, R., Matsumoto, N., Yoshida, Y., Mikawa, R., Katayama, A., Wada, J., Seki, M., Suzuki, Y., Iwama, A., Nakagami, H., Nagasawa, A., Morishita, R., Sugimoto, M., Okuda, S., . . . Minamino, T. (2021). Senolytic vaccination improves normal and pathological age-related phenotypes and increases lifespan in progeroid mice. Nature Aging. https://doi.org/10.1038/s43587-021-00151-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.